ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2447

Early Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient: Could We Avoid It?

Session Information

Category: Trainee Case Report

  • 1902 Transplantation: Clinical


  • Ivaturi, Kaushik, University of California Irvine, Irvine, California, United States
  • Tantisattamo, Ekamol, University of California Irvine, Irvine, California, United States

Although uncommon, ganciclovir-resistant cytomegalovirus (GR-CMV) can lead to a therapeutic challenge given drug nephrotoxicity. Here we report a case of GR-CMV infection during early post-kidney transplant (KT).

Case Description

A 41-year-old woman with ESRD received the second KT in February 2019 with rATG induction. She also received rituximab one dose for pre-KT donor specific HLA antibodies. Maintenance immunosuppression are tacrolimus, mycophenolate sodium (MPS), and prednisone. Serum creatinine slowly trended down to the baseline of 1.3mg/dL at 3 month post-KT. CMV IgG serostatus was D+/R-. She received a 6-month CMV prophylaxis with a renally-adjusted dose of valganciclovir 450 mg twice weekly for 1 month, which was increased to 450 mg twice daily for 5 more months. 4 months after the CMV prophylaxis was completed, she developed asymptomatic CMV viremia with a titer up to peak of 47,643 IU/ml. Valganciclovir 900 mg twice daily was started and MPS was decreased. CMV PCR slowly decreased to 440 IU/ml after 1 month of therapy. Despite continuation of valganciclovir, CMV PCR became rapidly increased to 3,349 IU/ml [Figure]. A CMV genetic resistance test revealed a UL97, but not UL54 gene mutation. Foscarnet was started and CMV PCR was decreased. Allograft function has been at the baseline.


Our patient has several risk factors for GR-CMV including high-risk CMV serostatus, prolonged exposure to low-dose oral valganciclovir prophylaxis, and intensified immunosuppression including rituximab. Given current treatment for GR-CMV remains limited with drug toxicity, adequate dose of CMV prophylaxis is critical to avoid GR-CMV. Pattern of CMV PCR after initiation of therapy should also raise a suspicion for GR-CMV and genetic CMV resistance testing is of paramount in early diagnosis. Novel preventive and therapeutic options may mitigate the risk of GR-CMV and drug-induced renal allograft toxicity.